References
Amit, V. K., & Kathiresan, S. (2016). Lipoprotein(a): Physiological and pathophysiological perspectives. Trends in Endocrinology & Metabolism, 27(6), 364-375.
Arabidze, G. G. (2018). Immunology of atherosclerosis: Modern achievements and prospects. Therapist, (12), 4-25.
Arun, S. (2008). High-sensitivity C-reactive protein and cardiovascular disease: A resolute belief or an elusive link? Circulation, 118(20), 2089-2097.
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., ... & Muntner, P. (2019). Heart disease and stroke statistics—2019 update: A report from the American Heart Association. Circulation, 139(10), e56-e528.
Berberich, A. J., & Hegele, R. A. (2019). Dyslipidemia: Genetic aspects. In Oxford Textbook of Endocrinology and Diabetes (pp. 579-586). Oxford University Press.
Brown, M. S., & Goldstein, J. L. (2009). A receptor-mediated pathway for cholesterol homeostasis. Science, 232(4746), 34-47.
Conrad, A., & Bartenschlager, R. (2013). Viral hepatitis: Mechanisms of viral persistence and a path to a cure. Nature Reviews Gastroenterology & Hepatology, 10(12), 743-755.
Dekker, J. M., et al. (2010). The role of lipoprotein-associated phospholipase A2 in cardiovascular disease. Journal of Clinical Lipidology, 4(4), 293-300.
Hayashida, K., et al. (2013). LOX-1: A potential therapeutic target for vascular disorders. Journal of Molecular and Cellular Cardiology, 66, 103-110.
Herz, J., et al. (1987). LDL receptor-mediated endocytosis: Concepts emerging from familial hypercholesterolemia. Science, 235(4796), 680-685.
Hsue, P. Y., et al. (2015). Cardiovascular disease in HIV-infected patients. Journal of the American College of Cardiology, 65(8), 830-839.
Jayaraman, S., et al. (1999). Prognostic value of lipoprotein-associated phospholipase A2 in cardiovascular disease. New England Journal of Medicine, 341(1), 19-26.
Khera, A. V., & Kathiresan, S. (2016). Lipoprotein(a) and its role in atherosclerosis: A comprehensive review. Circulation Research, 119(7), 1049-1062.
Klimchuk, A. V., & Kozlov, V. A. (2021). Atherosclerosis: Pathogenetic mechanisms and prospects for correction. Bulletin of Experimental Biology and Medicine, 171(5), 597-600.
Klimov, A. N., et al. (2003). Pathogenesis and pathogenetic mechanisms of atherosclerosis. Advances in Cardiovascular Diseases, 44(4), 345-355.
Libby, P., et al. (2005). Inflammation and atherosclerosis: From the endothelium to the plaque. Journal of the American College of Cardiology, 46(1), C7-C19.
Libby, P., et al. (2010). Inflammation and its role in human disease. Nature, 473(7347), 333-342.
Libby, P., et al. (2019). Atherosclerosis: A multifactorial disease. Cell, 179(2), 283-297.
Monami, M., et al. (2019). PCSK9 inhibitors and cardiovascular outcomes: A meta-analysis of randomized clinical trials. Journal of the American Heart Association, 8(10), e012924.
Musunuru, K., & Kathiresan, S. (2016). Genetics of coronary artery disease. Annual Review of Genomics and Human Genetics, 17, 377-410.
Nelson, R. H. (2013). Hyperlipidemia as a risk factor for cardiovascular disease. Primary Care: Clinics in Office Practice, 40(1), 195-211.
Nikolic, D., et al. (2011). Lipoprotein-associated phospholipase A2 and cardiovascular risk. Current Medicinal Chemistry, 18(12), 1762-1771.
Nordestgaard, B. G. (2010). Atherosclerosis and lipoprotein metabolism: New insights. European Heart Journal, 31(24), 2983-2991.
Prudnikov, A. V., & Shchupakova, N. A. (2018). Autoimmune mechanisms of atherosclerosis. Autoimmunity Reviews, 17(5), 533-539.
Roden, M., et al. (2016). Mechanisms of lipoprotein(a) in atherosclerosis. European Heart Journal, 37(15), 1175-1182.
Rohatgi, A. (2011). HDL cholesterol efflux capacity and cardiovascular disease. New England Journal of Medicine, 364(2), 127-135.
Shimano, H. (2009). SREBP: A mediator of cholesterol metabolism. Journal of Lipid Research, 50(Suppl), S120-S125.
Virani, S. S., et al. (2016). Lipoprotein(a) as a cardiovascular risk factor: Current understanding and future directions. Journal of the American College of Cardiology, 68(22), 2395-2402.
Wang, N., et al. (2018). Mechanisms of LDL receptor regulation. Annual Review of Biochemistry, 87, 789-817.
Weber, C., & Ley, K. (2014). Pathogenesis of atherosclerosis. Journal of Internal Medicine, 276(2), 114-126.
Williams, K. J., & Krauss, R. M. (2017). Hyperlipidemia and cardiovascular risk: Mechanisms and interventions. Journal of Clinical Endocrinology & Metabolism, 102(11), 3936-3944.
Zakrzewska, K. E., & Czarna, A. (2021). Genetics and molecular biology of LDL receptor. Journal of Human Genetics, 66(7), 647-661.